CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced on Monday, that it has named Roger J Pomerantz, MD, FACP as its new chairman effective immediately.
Presently, Dr Pomerantz is the president, chief executive officer and chairman of the board of directors of ContraFect. Dr Pomerantz has extensive board experience and presently serves on the boards of Intec Pharma and VerImmune, in addition to ContraFect. He also serves as the chairman of the Scientific Advisory Board of Aridis Pharmaceuticals. He was also a Venture Partner at Flagship Pioneering from 2014 until 2019. Earlier, he served as the president, chief executive officer and chairman of the board of Seres Therapeutics, where he continues to serve as advisor. Prior to joining Seres, he was senior vice president, worldwide head of Licensing & Acquisition at Merck & Co Inc and prior to that was senior vice president and global franchise head of Infectious Diseases at Merck. Prior to joining Merck, he was global head of Infectious Diseases for Johnson & Johnson Pharmaceuticals.
Yehiel Tal, CollPlant chief executive officer, said, 'Dr Pomerantz's extensive knowledge of the life science industry as a clinician, senior executive and board member is exactly what we need as we bolster our strategic partnerships and clinical development efforts for our recombinant human collagen (rhCollagen) technology platform. Roger is an excellent addition to our team and will play an integral role in our mission to provide optimal treatment options for patients through ground-breaking solutions in the field of regenerative and aesthetic medicine.'
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial